Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 9/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 8/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3053339 | 0.89 | NR1I2 (0.39) | NR1I2CYP2C9P2RX3P2RX2GRIA2 | |
| SCHEMBL3057693 | 0.89 | NR1I2 (0.43) | NR1I2CYP2C9P2RX3P2RX2GRIA2 | |
| SCHEMBL3073168 | 0.85 | NR1I2 (0.44) | NR1I2CYP2C9P2RX3P2RX2CYP3A4 | |
| SCHEMBL3073172 | 0.85 | NR1I2 (0.44) | NR1I2CYP2C9P2RX3P2RX2CYP3A4 | |
| SCHEMBL3064078 | 0.85 | NR1I2 (0.44) | NR1I2CYP2C9P2RX3P2RX2CYP3A4 | |
| SCHEMBL3065989 | 0.84 | CA12 (0.39) | CYP11B2DHODH | |
| SCHEMBL13092681 | 0.83 | NR1I2 (0.49) | NR1I2CYP2C9P2RX3P2RX2 | |
| SCHEMBL13092613 | 0.81 | NR1I2 (0.48) | NR1I2CYP2C9P2RX3P2RX2 | |
| SCHEMBL3067384 | 0.80 | NR1I2 (0.41) | NR1I2CYP2C9P2RX3P2RX2GRIA2 | |
| SCHEMBL3063222 | 0.79 | NR1I2 (0.48) | NR1I2CYP2C9P2RX3P2RX2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2215049-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2019-06-12 | — | — | EP | disclosed |
| US-8247401-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | disclosed |
| EP-2215049-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | Merck Sharp & Dohme Corp. (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009058298-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK & CO., INC. (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | NR1I2 598/4885CYP2C9 4126/4885P2RX3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.